Arcutis Biotherapeutics, Inc.

NasdaqGS:ARQT Stock Report

Market Cap: US$3.0b

Arcutis Biotherapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:ARQT Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
11 May 26SellUS$4,673Patrick BurnettIndividual222US$21.05
11 May 26SellUS$9,157Latha VairavanIndividual435US$21.05
04 May 26SellUS$16,150Patrick BurnettIndividual684US$23.61
04 May 26SellUS$20,872Masaru MatsudaIndividual884US$23.61
04 May 26SellUS$74,893Todd WatanabeIndividual3,172US$23.61
04 May 26SellUS$31,662Latha VairavanIndividual1,341US$23.61
02 Mar 26SellUS$158,320Patrick BurnettIndividual6,287US$25.91
02 Mar 26SellUS$92,846Larry EdwardsIndividual3,687US$25.91
02 Mar 26SellUS$940,528Todd WatanabeIndividual37,349US$25.91
02 Mar 26SellUS$71,844Latha VairavanIndividual2,853US$25.91
02 Mar 26SellUS$169,877Masaru MatsudaIndividual6,746US$25.91
02 Feb 26SellUS$93,707Patrick BurnettIndividual3,675US$25.50
02 Feb 26SellUS$52,323Larry EdwardsIndividual2,052US$25.50
02 Feb 26SellUS$505,710Todd WatanabeIndividual19,833US$25.50
02 Feb 26SellUS$203,554Masaru MatsudaIndividual7,983US$25.50
02 Feb 26SellUS$33,658Latha VairavanIndividual1,320US$25.50
31 Dec 25SellUS$49,560Patrick BurnettIndividual1,697US$29.39
20 Nov 25SellUS$118,792Halley GilbertIndividual4,312US$27.55
19 Nov 25SellUS$72,135Masaru MatsudaIndividual2,550US$28.50
06 Nov 25SellUS$732,927Larry EdwardsIndividual29,131US$25.16
03 Nov 25SellUS$64,806Patrick BurnettIndividual2,622US$25.40
03 Nov 25SellUS$178,156Masaru MatsudaIndividual7,208US$25.40
03 Nov 25SellUS$285,399Todd WatanabeIndividual11,547US$25.40
03 Nov 25SellUS$2,175Latha VairavanIndividual88US$24.72
02 Oct 25SellUS$90,263Larry EdwardsIndividual4,504US$20.78
19 Aug 25SellUS$28,281Patrick BurnettIndividual1,750US$16.16
04 Aug 25SellUS$37,564Patrick BurnettIndividual2,622US$14.33
04 Aug 25SellUS$90,687Masaru MatsudaIndividual6,330US$14.33
04 Aug 25SellUS$1,275Latha VairavanIndividual89US$14.33
04 Aug 25SellUS$165,429Todd WatanabeIndividual11,547US$14.33

Insider Trading Volume

Insider Buying: ARQT insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of ARQT?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders2,044,5561.48%
VC/PE Firms9,874,5117.16%
Hedge Funds20,598,57714.9%
Institutions105,429,80776.4%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 80.79% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.86%
Suvretta Capital Management, LLC
12,327,000US$300.5m3.03%7.11%
7.89%
Frazier Life Sciences Management, LP
9,874,511US$240.7m0%6.18%
7.36%
BlackRock, Inc.
9,200,411US$224.3m1.11%no data
6.61%
Rubric Capital Management LP
8,271,577US$201.7m0%2.19%
5.03%
State Street Global Advisors, Inc.
6,296,197US$153.5m14.7%no data
4.53%
Polar Capital Holdings Plc
5,666,940US$138.2m1.99%0.29%
3.98%
Jennison Associates LLC
4,980,770US$121.4m-26.3%0.07%
3.89%
Vanguard Capital Management, LLC
4,871,536US$118.8m0%no data
3.44%
Gilder Gagnon Howe & Co. LLC
4,304,010US$104.9m-3.36%1.1%
3.32%
Morgan Stanley
4,156,457US$101.3m-2.18%0.01%
2.85%
UBS Asset Management AG
3,566,395US$86.9m2.63%0.01%
2.43%
Geode Capital Management, LLC
3,045,306US$74.2m10.6%no data
2.12%
Medical Strategy GmbH
2,651,906US$64.7m0%4.1%
2%
D. E. Shaw & Co., L.P.
2,496,222US$60.9m-6.96%0.05%
1.94%
Marshall Wace LLP
2,431,778US$59.3m435%0.06%
1.83%
Franklin Resources, Inc.
2,285,820US$55.7m20.3%0.02%
1.78%
Driehaus Capital Management LLC
2,226,029US$54.3m-13.1%0.24%
1.56%
Vanguard Portfolio Management, LLC
1,954,685US$47.7m0%no data
1.56%
Bank of America Corporation
1,945,675US$47.4m33.9%0.01%
1.48%
Janus Henderson Group plc
1,854,566US$45.2m1.34%0.02%
1.17%
American Century Investment Management Inc
1,463,228US$35.7m-0.27%0.01%
1.09%
Oberweis Asset Management, Inc.
1,365,941US$33.3m69%0.64%
1.08%
Pivotal BioVenture Partners LLC
1,355,892US$33.1m-0.79%9.2%
0.99%
Ensign Peak Advisors, Inc.
1,244,387US$30.3m-34.6%0.05%
0.97%
The Goldman Sachs Group, Inc.
1,218,890US$29.7m4.92%0.01%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/14 22:48
End of Day Share Price 2026/06/12 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Arcutis Biotherapeutics, Inc. is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Richard J. LawGoldman Sachs
null nullGuggenheim Securities, LLC
Seamus FernandezGuggenheim Securities, LLC